U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive
GREENVILLE, N.C., April 16, 2021 /PRNewswire/ --Â Mayne Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) for the prevention of pregnancy. NEXTSTELLIS is the first and only contraceptive pill containing E4, a naturally occurring estrogen, now produced from a plant source, with a unique mechanism of action that offers potential advantages over other estrogens. "When speaking with patients about their contraceptive options, one of the most common concerns is side effects," said Mitchell...
Source: johnsoncitypress.com